Chris Bradley 0:04 Welcome back to the Sustainable Design Lab podcast. I'm Chris Bradley.

Brodie Vander Dussen 0:08 And I'm Brodie Van der Dusen. Today, we're continuing our coaching masterclass with a deeper look at biopharmaceutical cold chain. This segment has raised the bar for what good actually means in temperature controlled packaging. That includes life sciences more broadly and the rapid growth of GLP one therapies in particular.

Chris Bradley 0:27 In episode one, I laid down the foundation, the physics, the materials, the systems. And in this episode two, this is where that foundation gets tested. Biopharmaceutical logistics is the environment where thermal science, regulatory expectations, and real world operations all converge.

Brodie Vander Dussen 0:46 And it's where the impact becomes very real because when cold chain fails here, it's not just a logistics issue, it's a patient issue. So let's get into

Chris Bradley 1:02 it.

Brodie Vander Dussen 1:03 This first section we have is biopharmaceutical cold chains, where systems break.

Chris Bradley 1:09 Okay. So in the last episode, we talked about cold chain as a system. Heat transfer, insulation, refrigerants, lanes, all of that still applies here, but biopharmaceutical cold chain adds something else, consequences. In biopharma, cold chain isn't protecting food quality or shelf life, it's protecting molecular structure, protein folding, cell viability. A single temperature excursion doesn't just mean a damaged shipment. It can mean a failed batch, a regulatory investigation, or a missed dose for a client who doesn't have time to wait. Same physics, much higher stakes.

Brodie Vander Dussen 1:48 And this is where the systems that look good on paper often fail in the real world. So let's talk a little bit about the biopharma risk stack.

Chris Bradley 1:56 Biopharma cold chain risk is layered. It's not additive, it's stacked. So let's break that down. First, product sensitivity. Most biologics are fragile by definition. They don't degrade slowly. They cross thresholds. And once that threshold is crossed, the damage is invisible, but it's irreversible. So in practice, it's common for shipments to remain largely in range while still experiencing brief sub spec exposure. No visible signal, no obvious damage, but stability data may still indicate a loss of viability. The second is time at temperature. So stability isn't binary, it's cumulative. So temperature recovery does not equal damage recovery. A product that spends time outside of its specification does not reset once it comes back into range. The clock continues to run. And then third is regulatory exposure. In biopharma, excursions trigger investigations before replacement, deviations reports, root cause analysis, corrective and preventative actions. And sometimes the product survives, but the documentation does not. And finally, patient impact. This isn't inventory. It's therapy. Cold chain here is part of the clinical outcome, whether it's framed that way or not. ons before replacement, deviations reports, root cause analysis, corrective and preventative actions. And sometimes the product survives, but the documentation does not. And finally, patient impact. This isn't inventory. It's therapy. Cold chain here is part of the clinical outcome, whether it's framed that way or not.

Brodie Vander Dussen 3:19 So let's talk a little bit about GLP one specifically and how the rise in that, the scale of that really exposes weak systems.

Chris Bradley 3:28 That's a great point, Brodie. GLP one products illustrate how cold chain risk can hide in plain sight. On paper, these shipments appear manageable. They're not cryogenic. They're not gene or cell therapy, but scale changes everything. GLP one programs often involve high shipment velocity to hundreds of thousands of in home shipments or clinics. And when this demand accelerates, operational variability increases. So packouts are assembled faster, conditioning windows tighten, small inconsistencies begin to compound. And this shows up not as catastrophic failures, but as subtle instability signals that trigger investigations. The installation may be technically sound, but scale amplifies minor design and process weaknesses. So GLP one cold chain doesn't fail because it's exotic, it fails because it's relentless.

Brodie Vander Dussen 4:28 You know, we hear the term lane validated all the time, but biopharma lanes rarely behave like other cold chain lanes. So can you talk a little bit about why lane based design breaks down?

Chris Bradley 4:39 Sure. So I think most failures don't occur during planned transit segments. They occur between them. So unplanned dwell, tarmac delays, customs holds, warehouse congestion, these events often fall outside of validation profiles, but still occur within normal operations. So cold chain systems tend to fail at the handoffs, where responsibility changes and control is the lowest. A system is only as strong as the moments that no one models.

Brodie Vander Dussen 5:12 Which brings us to temperature bands. Which ones would you say that failed most? ill occur within normal operations. So cold chain systems tend to fail at the handoffs, where responsibility changes and control is the lowest. A system is only as strong as the moments that no one models. Which brings us to temperature bands. Which ones would you say that failed most?

Chris Bradley 5:17 Let's talk about where failures most often cluster, not where people assume. So first, let's look at one of the most common bands, two to eight degrees c. This is the most common temperature band. It's where the GLP ones live, and it's the one that's the most deceptive. Heat is the obvious concern, but freeze damage is often underestimated. It is well documented that ice heavy packouts designed to increase the safety margin can create localized sub zero exposure near walls and corners. So the center of the shipper may remain in range and monitoring may show no alarm, but the product near the edge may still be compromised. Second, controlled room temperature in the 15 to 25 degrees c. This is often treated as a really low risk type of shipment. But in reality, CRT shipments are exposed to both heat and cold. Seasonal extremes really matter here. They fail not because they are complex, but because they are underestimated. Frozen and deep frozen systems are more operationally demanding, but they're often far more predictable. These middle bands are where complacency lives.

Brodie Vander Dussen 6:33 Let's get into section five where we talk a little bit about hidden failure

Chris Bradley 6:37 modes. Sure. So most cold chain systems don't fail because insulation is inadequate. They fail because of interactions. Edge loss under vibration, panel shift during handling, micro gaps that appear outside of laboratory conditions, PCM placement optimized for diagrams rather than heat ingress, payloads acting as heat sinks, And then there is this whole human layer. So variability and pack out execution, not everybody is gonna pack it out exactly the same way. And this also leads to inconsistent conditioning, small timing deviations. So cold chain systems tend to fail where design meets reality.

Brodie Vander Dussen 7:19 The design may be validated, but the execution often isn't, which brings us to section six when we talk a little bit about monitoring and false competence.

Chris Bradley 7:29 So monitoring is really critical, but it's often misunderstood. So data loggers do not prevent excursions. They record them. So without design changes, data becomes retrospective evidence, not true protection. Confidence does not come from visibility alone. It comes from systems engineered to tolerate this real world variability.

Brodie Vander Dussen 7:53 How does parcel versus bulk biopharma shipments really differ? hey record them. So without design changes, data becomes retrospective evidence, not true protection. Confidence does not come from visibility alone. It comes from systems engineered to tolerate this real world variability. How does parcel versus bulk biopharma shipments really differ?

Chris Bradley 7:57 So I would say bulk biopharma shipments behave very differently. Palletized systems, like our new pallet shield shipper, benefit from high thermal mass and fewer handoffs. They often perform very well under conditions that would challenge a parcel shipper. But when bulk systems fail, the impact is concentrated. One refrigeration outage, one prolonged delay, and the entire lot may be effective. So parcel failures tend to be smaller and more frequent, and bulk failures are rarer, but far more consequential. So effective cold chain strategy recognizes this and designs very differently for each one of these scenarios.

Brodie Vander Dussen 8:41 And how would you say sustainability plays in pressuring the biopharma market?

Chris Bradley 8:47 So, historically, biopharma cold chain has leaned towards over engineering. More foam, more PCM, more margin, not because it was more efficient, but because it feels safe. And so high volume programs like TLP ones, which are getting into millions of shipments a month, are changing the equation. So when scaled, inefficiency becomes extremely visible. Dim weight compounds, material choices matter, end of life pathways come under scrutiny, and sustainability pressure is not slowing innovation, it's forcing more disciplined engineering. And the real tension is not performance versus sustainability. It's fear versus data.

Brodie Vander Dussen 9:30 We talked a little bit about every aspect of risk and failures. What does good look like when it comes to biopharma cold chain packaging?

Chris Bradley 9:39 So high performing biopharma cold chain systems share a few common traits. One, they are right sized to the actual lanes, not hypothetical extremes. They are repeatable and operationally realistic. They have clear, credible end of life pathways. And most importantly, they prevent excursions rather than simply documenting them. The best systems do not feel heroic. They feel boring. And boring is exactly what you want when patient outcomes are on the line. If you take away three ideas from this episode, let it be these three. One, GLP one therapies show how scale exposes weak systems. Two, many biopharma failures occur quietly before alarms are ever triggered. And three, sustainability pressure is not optional. It's forcing better design.

Brodie Vander Dussen 10:31 And next, we'll bring this all together. In the final episode of this series, we'll focus on design strategies, how to choose systems without guessing, how to engineer margin without overbuilding, and how to design cold chain systems that hold in the real world. That's where cold chain stops reacting and starts being engineered. we'll bring this all together. In the final episode of this series, we'll focus on design strategies, how to choose systems without guessing, how to engineer margin without overbuilding, and how to design cold chain systems that hold in the real world. That's where cold chain stops reacting and starts being engineered.

Chris Bradley 10:49 So if you found this master class episode valuable, please make sure to subscribe to the Sustainable Design Lab podcast so you don't miss the next episode where we'll walk through the practical framework for designing cold chain systems from the ground up.

Brodie Vander Dussen 11:03 Thanks for listening. We'll see you next time.